Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Common Equity (2024 - 2025)

Evommune (EVMN) has disclosed Common Equity for 2 consecutive years, with $205.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 242.52% to $205.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $205.6 million, a 242.52% increase, with the full-year FY2025 number at $205.6 million, up 242.52% from a year prior.
  • Common Equity was $205.6 million for Q4 2025 at Evommune, up from -$183.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $205.6 million in Q4 2025 to a low of -$183.1 million in Q3 2025.